Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II open label study assessing Piclidenoson

Trial Profile

Phase II open label study assessing Piclidenoson

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 21 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Piclidenoson (Primary)
  • Indications Oculocerebrorenal syndrome
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Apr 2025 According to Can-Fite Biopharma media release, A Phase II design has been completed and preparatory work is being undertaken to initiate the study that will be conducted by Dr. Franchesca Emma from the Division of Nephrology, Bambino Gesu Children's Hospital-IRCCS Rome Italy.
    • 26 Mar 2025 New trial record
    • 19 Mar 2025 According to Can-Fite Biopharma media release, Dr. Franchesca Emma from the Division of Nephrology, Bambino Gesu Childrens Hospital - IRCCS Rome Italy, will be the principal investigator of the study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top